<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - EMPAGLIFLOZIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>EMPAGLIFLOZIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Type II diabetes as monotherapy (if metformin inappropriate)</span>,
                <span class="indication">Type II diabetes in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;84 years</strong><br/>
                10 mg once daily, increased to 25 mg once daily if necessary and if tolerated.</li>
              <li class="dose adult"><strong>For adults 85 years and over</strong><br/>
                Initiation not recommended.</li>
            </ul>
          </section>
        </section>
        
            <section class="doseAdjustments">
                <h3>Dose adjustments due to interactions</h3>
              <p>Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.</p>
            </section>
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid in severe impairment&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose to 10&#8239;mg once daily if eGFR falls persistently below 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid initiation if eGFR below 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>Avoid if eGFR is persistently below 45&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Diabetic ketoacidosis</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Genital infection, hypoglycaemia (in combination with insulin or sulfonylurea), polyuria, pruritus, urinary tract infection,
              </p>
              <p>
                <strong>uncommon:</strong> Dysuria, volume depletion,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA336</h3>
              <p outputclass="title">Empagliflozin in combination therapy for treating type 2 diabetes (March 2015)</p> <p>Empagliflozin in a dual therapy regimen in combination with metformin is an option for the treatment of type 2 diabetes, only if:</p> <ul> <li>a sulfonylurea is contraindicated or not tolerated, <b>or</b> </li> <li>the patient is at significant risk of hypoglycaemia or its consequences.</li> </ul> <p>Empagliflozin in a triple therapy regimen is an option for the treatment of type 2 diabetes in combination with:</p> <ul> <li>metformin and a sulfonylurea <b>or</b> </li> <li>metformin and a thiazolidinedione.</li> </ul> <p>Empagliflozin in combination with insulin with or without other antidiabetic drugs is an option for the treatment of type 2 diabetes.</p> <p>Patients currently receiving empagliflozin whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA336">www.nice.org.uk/TA336</xref>
                <a href="http://www.nice.org.uk/TA336" target="_blank">www.nice.org.uk/TA336</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice (June 2015): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin or empagliflozin)</h3>
              <p>Serious and potentially life-threatening cases of diabetic ketoacidosis (DKA) have been reported in patients taking the SGLT2 inhibitor empagliflozin for type 2 diabetes. To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:</p><ul>
            <li>Test for raised ketones in patients presenting with symptoms of DKA, even if plasma glucose levels are near-normal; omitting this test could delay diagnosis of DKA.</li>
            <li>Discontinue treatment if DKA is suspected.</li>
            <li>If DKA is confirmed, take appropriate measures to correct the DKA and monitor glucose levels.</li>
            <li>Patients should be advised on how to recognise the signs and symptoms of DKA such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness, and to seek prompt medical attention if symptoms of DKA develop.</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiovascular disease (increased risk of volume depletion)
          </li>
          <li>
            complicated urinary tract infections&#8212;consider temporarily interrupting treatment
          </li>
          <li>
            concomitant antihypertensive therapy (increased risk of volume depletion)
          </li>
          <li>
            elderly patients aged over 75 years (increased risk of volume depletion)
          </li>
          <li>
            heart failure
          </li>
          <li>
            history of hypotension (increased risk of volume depletion)
          </li>
          <li>
            patients at increased risk of volume depletion
          </li>
          <li>
            predisposition to fluid disturbances e.g. gastro-intestinal illness, concomitant use of diuretics (increased risk of volume depletion)
          </li>
        </ul>
        <ul>
          <li>
            <p>Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Determine renal function before treatment and before initiation of concomitant drugs that may reduce renal function, then at least annually thereafter.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of EMPAGLIFLOZIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP101867"><a href="../medicinalForm/PHP101867.html" data-target="#PHP101867" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
